Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pernix Therapeutics Holdings Inc (NASDAQ:PTX)

4.70
Delayed Data
As of Aug 28
 +0.10 / +2.17%
Today’s Change
4.25
Today|||52-Week Range
12.88
-49.95%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$286.9M

Company Description

Pernix Therapeutics Holdings, Inc. is a pharmaceutical company, which is focused on the sales, marketing and development of branded and generic pharmaceutical products for the pediatric market. Its pediatric products are focused on allergy and upper respiratory, including nasal, chest congestion and cough, antibiotics, and dermatology. Pernix Therapeutics Holdings branded products CEDAX, an antibiotic for middle ear infections; NATROBA, which is a topical treatment for head lice; OMECLAMOX-PAK, a ten-day therapy of omeprazole delayed-release capsules, clarithromycin tablets and amoxicillin capsules for the treatment of helicobacter pylori infection and duodenal ulcer disease; and REZYST, which is a probiotic blend to promote dietary management. The company promotes its branded pediatric and generic products through its sales force wholly-owned subsidiary, Macoven Pharmaceuticals. Pernix Therapeutics Holdings was founded in March 9, 2010 and is headquartered in The Woodlands, TX.

Contact Information

Pernix Therapeutics Holdings, Inc.
10 North Park Place
Morristown New Jersey 07960
P:(800) 793-2145
Investor Relations:
180079321451009

Employees

Shareholders

Other institutional42.68%
Mutual fund holders21.07%
Individual stakeholders16.99%

Top Executives

Douglas L. DrysdaleChairman, President & Chief Executive Officer
Terence S. NovakChief Operating Officer
Sanjay S. PatelChief Financial Officer & Head-Investor Relations
Jessica OienVice President-Compliance
Barry J. SiegelSenior Vice President & General Counsel